Covid-19 roundup: Swiss biotech halts in-pa­tient PhII study; Hous­ton-based vac­cine and Chi­nese mR­NA shot nab EUAs in In­done­sia

An­oth­er Covid-19 study is hit­ting the brakes as a Swiss biotech is paus­ing its Phase II tri­al in pa­tients hos­pi­tal­ized with Covid-19.

Ki­narus Ther­a­peu­tics an­nounced on Fri­day that the Da­ta and Safe­ty Mon­i­tor­ing Board (DSMB) has re­viewed the com­pa­ny’s Phase II study for its can­di­date KIN001 and has rec­om­mend­ed that the study be stopped.

Ac­cord­ing to Ki­narus, the DSMB stat­ed that there was a low prob­a­bil­i­ty to show sta­tis­ti­cal­ly sig­nif­i­cant re­sults as the num­ber of Covid-19 pa­tients that are in the hos­pi­tal is low­er than at oth­er points in the pan­dem­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.